Human gene therapy - immunogenicity perspective
Interviewee/Contributor
J Fraser Wright
Organisation
Stanford University School of Medicine
Strategy
Galapagos shows that the fittest can survive
Interviewee/Contributor
Piet Wigerinck and Walid Abi-Saab
Organisation
Galapagos NV
Exploiting enzymes from the Arctic Ocean
Interviewee/Contributor
Christian Jørgensen
Organisation
Biotec Pharmacon ASA
Technology for direct cell reprogramming
Interviewee/Contributor
Julian Gough
Organisation
Mogrify Ltd
Vivoryon Therapeutics tests Alzheimer's drug
Interviewee/Contributor
Ulrich Dauer
Organisation
Vivoryon Therapeutics AG
Taking on the Alzheimer's conundrum
Interviewee/Contributor
Reisa Sperling
Organisation
Harvard Medical School
Revisiting antibody-drug conjugates
Interviewee/Contributor
Chris Martin
Organisation
ADC Therapeutics SA
Why private equity is investing in biopharma
Interviewee/Contributor
Emma Dabbs
Organisation
Novasecta Ltd
Dual inhibition of intracellular enzymes
Interviewee/Contributor
Tara Rheault Margot MacDonald-Berko
Organisation
Verona Pharma Plc
The use of patient registries for regulatory purposes
Interviewee/Contributor
Peter Charlish
Organisation
MedNous